EA032713B1 - Терапевтические ингибирующие соединения - Google Patents
Терапевтические ингибирующие соединения Download PDFInfo
- Publication number
- EA032713B1 EA032713B1 EA201691354A EA201691354A EA032713B1 EA 032713 B1 EA032713 B1 EA 032713B1 EA 201691354 A EA201691354 A EA 201691354A EA 201691354 A EA201691354 A EA 201691354A EA 032713 B1 EA032713 B1 EA 032713B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methyl
- chloro
- benzyl
- isonicotinamide
- oxopyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361921995P | 2013-12-30 | 2013-12-30 | |
| US201462025203P | 2014-07-16 | 2014-07-16 | |
| PCT/US2014/072851 WO2015103317A1 (en) | 2013-12-30 | 2014-12-30 | Therapeutic inhibitory compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691354A1 EA201691354A1 (ru) | 2016-12-30 |
| EA032713B1 true EA032713B1 (ru) | 2019-07-31 |
Family
ID=53493998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691354A EA032713B1 (ru) | 2013-12-30 | 2014-12-30 | Терапевтические ингибирующие соединения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10266515B2 (enExample) |
| EP (1) | EP3089746A4 (enExample) |
| JP (1) | JP6759100B2 (enExample) |
| KR (1) | KR20160106627A (enExample) |
| CN (1) | CN106061480B (enExample) |
| AU (2) | AU2014373735B2 (enExample) |
| BR (1) | BR112016015449A8 (enExample) |
| CA (1) | CA2935683A1 (enExample) |
| EA (1) | EA032713B1 (enExample) |
| MX (1) | MX2016008688A (enExample) |
| WO (1) | WO2015103317A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| ES2608474T3 (es) | 2010-04-22 | 2017-04-11 | Vertex Pharmaceuticals Incorporated | Proceso de producción de compuestos indol cycloalkylcarboxamido |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| HUE14755117T2 (hu) | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| CA2935683A1 (en) | 2013-12-30 | 2015-07-09 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| ES2885181T3 (es) | 2014-04-15 | 2021-12-13 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
| AU2015289643B2 (en) * | 2014-07-16 | 2020-10-22 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| EP3404021A4 (en) | 2016-01-12 | 2019-09-11 | Nippon Chemiphar Co., Ltd. | VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| CN107033015B (zh) * | 2017-06-02 | 2019-04-30 | 南京欧信医药技术有限公司 | 一种药物中间体的合成方法 |
| PT3716952T (pt) | 2017-11-29 | 2022-04-14 | Kalvista Pharmaceuticals Ltd | Formas de administração que incluem um inibidor de calicreína plasmática |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN112770751A (zh) * | 2018-02-28 | 2021-05-07 | 爱顿制药公司 | 遗传性血管性水肿的治疗 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| IL311042B1 (en) | 2018-05-29 | 2026-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| EP4010333A1 (en) * | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| IL293588B1 (en) | 2019-12-04 | 2026-04-01 | Omeros Corp | 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| EP4587434A1 (en) * | 2022-09-15 | 2025-07-23 | Takeda Pharmaceutical Company Limited | N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema |
| WO2025001956A1 (zh) * | 2023-06-30 | 2025-01-02 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
| WO2025160190A1 (en) * | 2024-01-23 | 2025-07-31 | Retune Pharma Inc. | Therapeutic inhibitory compounds |
| WO2025247982A1 (en) * | 2024-05-29 | 2025-12-04 | Grünenthal GmbH | Piperazines which act as sstr4 modulators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090270407A1 (en) * | 2008-04-25 | 2009-10-29 | E. I. Du Pont De Nemours And Company | Fungicidal isoxazolidines |
| WO2010108733A1 (en) * | 2009-03-26 | 2010-09-30 | Syngenta Participations Ag | Insecticidal compounds |
| WO2013040436A2 (en) * | 2011-09-16 | 2013-03-21 | The Regents Of The University Of Michgian | Esx-mediated transcription modulators and related methods |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW212792B (enExample) * | 1991-09-13 | 1993-09-11 | Shell Internat Res Schappej B V | |
| IL108459A0 (en) * | 1993-02-05 | 1994-04-12 | Opjohn Company | 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| TW575562B (en) * | 1998-02-19 | 2004-02-11 | Agrevo Uk Ltd | Fungicides |
| IL149493A0 (en) * | 1999-11-10 | 2002-11-10 | Takeda Chemical Industries Ltd | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| WO2004078114A2 (en) * | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| GB0403155D0 (en) * | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| KR20070066988A (ko) * | 2005-12-22 | 2007-06-27 | 크리스탈지노믹스(주) | 단백질 키나아제 활성을 저해하는 아미노 피리미딘유도체와 이의 제조방법 및 이를 유효성분으로 함유하는약학 조성물 |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| CA2637620A1 (en) | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| EA200900779A1 (ru) * | 2006-12-14 | 2010-02-26 | Байер Шеринг Фарма Акциенгезельшафт | Производные дигидропиридина, полезные как ингибиторы протеинкиназы |
| JP2010518146A (ja) * | 2007-02-16 | 2010-05-27 | グラクソ グループ リミテッド | ベンゾフラン化合物 |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| WO2009119088A1 (ja) * | 2008-03-25 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2326625A1 (en) | 2008-07-18 | 2011-06-01 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives and their use as hstamine h3 antagonists |
| MX2011004570A (es) | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | Antagonistas del receptor p2x3 para el tratamiento del dolor. |
| GB201004739D0 (en) * | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| RU2632900C2 (ru) * | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| CN102904742B (zh) | 2011-07-29 | 2015-10-07 | 华为终端有限公司 | 对可执行节点的操作方法及系统 |
| EP2780014A4 (en) * | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| HRP20171459T1 (hr) * | 2012-12-07 | 2017-11-03 | F. Hoffmann - La Roche Ag | Piridin-2-amidi korisni kao agonisti cb2 |
| EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| HUE14755117T2 (hu) * | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CA2935683A1 (en) | 2013-12-30 | 2015-07-09 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| AU2015289643B2 (en) * | 2014-07-16 | 2020-10-22 | Attune Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
-
2014
- 2014-12-30 CA CA2935683A patent/CA2935683A1/en not_active Abandoned
- 2014-12-30 EA EA201691354A patent/EA032713B1/ru unknown
- 2014-12-30 MX MX2016008688A patent/MX2016008688A/es unknown
- 2014-12-30 CN CN201480076616.5A patent/CN106061480B/zh not_active Expired - Fee Related
- 2014-12-30 WO PCT/US2014/072851 patent/WO2015103317A1/en not_active Ceased
- 2014-12-30 US US14/800,631 patent/US10266515B2/en not_active Expired - Fee Related
- 2014-12-30 KR KR1020167020567A patent/KR20160106627A/ko not_active Ceased
- 2014-12-30 BR BR112016015449A patent/BR112016015449A8/pt active Search and Examination
- 2014-12-30 AU AU2014373735A patent/AU2014373735B2/en not_active Ceased
- 2014-12-30 EP EP14877414.4A patent/EP3089746A4/en not_active Withdrawn
- 2014-12-30 JP JP2016544593A patent/JP6759100B2/ja not_active Expired - Fee Related
-
2019
- 2019-04-02 US US16/373,391 patent/US20200031799A1/en not_active Abandoned
-
2020
- 2020-03-03 AU AU2020201550A patent/AU2020201550A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090270407A1 (en) * | 2008-04-25 | 2009-10-29 | E. I. Du Pont De Nemours And Company | Fungicidal isoxazolidines |
| WO2010108733A1 (en) * | 2009-03-26 | 2010-09-30 | Syngenta Participations Ag | Insecticidal compounds |
| WO2013040436A2 (en) * | 2011-09-16 | 2013-03-21 | The Regents Of The University Of Michgian | Esx-mediated transcription modulators and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016015449A8 (pt) | 2020-06-09 |
| JP6759100B2 (ja) | 2020-09-23 |
| US10266515B2 (en) | 2019-04-23 |
| AU2020201550A1 (en) | 2020-03-19 |
| EP3089746A1 (en) | 2016-11-09 |
| KR20160106627A (ko) | 2016-09-12 |
| AU2014373735A1 (en) | 2016-08-11 |
| WO2015103317A1 (en) | 2015-07-09 |
| EA201691354A1 (ru) | 2016-12-30 |
| AU2014373735B2 (en) | 2020-03-12 |
| CN106061480B (zh) | 2020-02-28 |
| MX2016008688A (es) | 2017-01-12 |
| US20200031799A1 (en) | 2020-01-30 |
| EP3089746A4 (en) | 2017-08-30 |
| CA2935683A1 (en) | 2015-07-09 |
| JP2017501205A (ja) | 2017-01-12 |
| US20180170906A1 (en) | 2018-06-21 |
| CN106061480A (zh) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014373735B2 (en) | Therapeutic inhibitory compounds | |
| US9855269B2 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| US10189810B2 (en) | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors | |
| US10221161B2 (en) | Inhibitors of plasma kallikrein | |
| US12233065B2 (en) | Inhibitors of RNA helicase DHX9 and uses thereof | |
| EA028626B1 (ru) | БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α | |
| TW201016676A (en) | Heterocyclic derivatives and methods of use thereof | |
| JP5036316B2 (ja) | アリールオキシ置換ベンズイミダゾール誘導体 | |
| TW200306180A (en) | New compounds | |
| CN120712252A (zh) | 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物 | |
| TW202337457A (zh) | 新穎苯并咪唑吡啶衍生物 | |
| CA3252935A1 (en) | THERAPEUTIC USE OF FIBROBLASTS INTENDED FOR USE IN WOUND HEALING | |
| CA3252707A1 (en) | TELESCOPE WITH OPTICAL ALIGNMENT SYSTEM | |
| HK1230502A1 (en) | Therapeutic inhibitory compounds | |
| HK1230502B (zh) | 治疗性抑制性化合物 | |
| HK1209107B (en) | Aminoquinazoline and pyridopyrimidine derivatives |